A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Pictrelisib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PEGGY
  • Sponsors Genentech
  • Most Recent Events

    • 01 Nov 2016 Interim results published in the Annals of Oncology.
    • 29 Sep 2015 Status changed from active, no longer recruiting to completed as result presented at the European Cancer Congress 2015
    • 23 Jan 2015 Planned End Date changed from 1 Jun 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top